- Report
- January 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,446GBP
- Report
- March 2024
- 192 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- April 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- November 2023
- 144 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Report
- October 2023
- 142 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1208EUR$1,250USD£1,038GBP
- Report
- June 2023
- 200 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- November 2021
- 295 Pages
Global
From €2659EUR$2,750USD£2,284GBP
€5317EUR$5,500USD£4,567GBP
- Report
- April 2023
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- July 2021
- 50 Pages
China
From €2514EUR$2,600USD£2,159GBP
- Report
- January 2021
- 143 Pages
China, Global
From €3000EUR$3,324USD£2,667GBP
- Report
- February 2024
- 174 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- April 2022
- 210 Pages
Global
From €5577EUR$5,769USD£4,791GBP
- Report
- April 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
Caspofungin is an antifungal drug used to treat a variety of fungal infections, including those caused by Candida species. It is a member of the echinocandin class of antifungal drugs, which are used to treat serious fungal infections in immunocompromised patients. Caspofungin is typically used in combination with other antifungal drugs, such as amphotericin B or fluconazole, to treat infections that are resistant to other antifungal agents. It is also used to treat infections caused by Aspergillus species, which are often difficult to treat.
Caspofungin is an important drug in the treatment of infectious diseases, as it is effective against a wide range of fungal infections. It is also well tolerated, with few side effects. As such, it is an important part of the infectious diseases drugs market.
Companies in the caspofungin market include Merck & Co., Pfizer, Astellas Pharma, and Bristol-Myers Squibb. Show Less Read more
